GL-2045 into Patients
GL-2045 is a recombinant Fc fusion protein in clinical trial designed to mimic the effects of the pooled human blood product IVIG in treating autoimmune disease. IVIG sells about $12 billion annually and is approved for use clinically in numerous autoimmune diseases. Gliknik has full ownership of GL-2045 and has all responsibility for ongoing clinical development of the compound.
After numerous intravenous cohorts and five subcutaneous cohorts in healthy participants, Gliknik intends to advance GL-2045 in CIDP and other patients.
GL-0719 Phase 1 Clinical Trial Underway
GL-0719 is a recombinant Fc fusion protein in clinical trial designed to selectively inhibit the classical and lectin complement pathways, leaving intact the alternative and terminal complement pathways. GL-0719 is designed for treating autoimmune diseases caused by over-activation of the classical and lectin pathways.
GL-0719 is currently being dosed in a phase 1 study to assess safety, tolerability, drug levels, complement inhibition of each pathway, and complement component levels.
GL-0719 is planned to be dosed intravenously and subcutaneously.
Our Approach
At Gliknik, our expertise is in modulation of the immune system and our mission is to discover and develop innovative biologics for people living with immune disorders.
Our determination to make a difference in the lives of individuals with autoimmune disease is evidenced by the assembly of talented scientists, augmented by our Board members, scientific advisors and a network of worldwide scientific and medical thought leaders.